Home › Compare › APTCF vs ADC

APTCF vs ADC: Dividend Comparison 2026

APTCF yields 1000000.00% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APTCF wins by $4.7683925249533696e+36M in total portfolio value
10 years
APTCF
APTCF
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full APTCF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — APTCF vs ADC

📍 APTCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPTCFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APTCF + ADC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
APTCF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTCF
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, APTCF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTCF + ADC for your $10,000?

APTCF: 50%ADC: 50%
100% ADC50/50100% APTCF
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

APTCF
No analyst data
Altman Z
-566.2
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTCF buys
0
ADC buys
0
No recent congressional trades found for APTCF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPTCFADC
Forward yield1000000.00% ✓4.13%
Annual dividend / share$2.00$3.10 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4% ✓
Portfolio after 10y$4.7683925249533696e+36M$178.9K ✓
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓$80,797.29
Total dividends collected$4.7683311610149396e+36M$156.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: APTCF vs ADC ($10,000, DRIP)

YearAPTCF PortfolioAPTCF Income/yrADC PortfolioADC Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,990$580.36+$100.00M → APTCF
2$934,786,450,701$934,679,439,252.34$12,301$860.26+$934786.44M → APTCF
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,104$1,298.62+$8165787108.56M → APTCF
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,691$2,008.16+$66665884190957.63M → APTCF
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$20,580$3,205.09+$508662171058048128.00M → APTCF
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$26,754$5,330.02+$3.62723524842849e+21M → APTCF
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$37,196$9,345.14+$2.417368115915061e+25M → APTCF
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$56,244$17,523.09+$1.5056740286145463e+29M → APTCF
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$94,286$35,736.21+$8.764771002818475e+32M → APTCF
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$178,949$80,797.29+$4.7683925249533696e+36M → APTCF

APTCF vs ADC: Complete Analysis 2026

APTCF — Stock

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. The company is headquartered in Burnaby, Canada.

Full APTCF Calculator →

ADC — REIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this APTCF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTCF vs SCHDAPTCF vs JEPIAPTCF vs OAPTCF vs KOAPTCF vs MAINAPTCF vs NNNAPTCF vs EPRTAPTCF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.